Sign In
Buy ALBO
$44.15
+0 (+0%)
At Close: May 26, 2023
Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US
06:10am, Wednesday, 21'st Jul 2021
Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat pruritus in all subtypes of progressive f
– Only once-daily drug indicated for the treatment of pruritus in PFIC –
– Only once-daily drug indicated for the treatment of pruritus in PFIC –
Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease
09:35am, Monday, 19'th Jul 2021
The European Commission (EC) has approved Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic cholestasis (PFIC). Bylvay is a potent, non
– First approval in the world of Bylvay for the treatment of PFIC –
Albireo to Present at the William Blair Biotech Focus Conference 2021
08:30am, Thursday, 08'th Jul 2021
BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief
Albireo's Bylvay Shows Further Evidence Of Sustained, Durable Effect In Pediatric Liver Disease Study
11:05am, Monday, 21'st Jun 2021
Albireo Pharma Inc (NASDAQ: ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization of A3907 in adult liver disease. Data wi
Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming EASL International Liver Congress
06:00am, Monday, 21'st Jun 2021
– Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters –
Albireo to Showcase New Data at the EASL International Liver Congress™ 2021
08:30am, Thursday, 10'th Jun 2021
– Phase 3 data presentations on long-term treatment and substantial clinical benefits of Bylvay™ (odevixibat) –
New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay™ (odevixibat) in PFIC
04:30pm, Thursday, 03'rd Jun 2021
– Data being presented show long-term benefits of Bylvay in children with PFIC –
Mirum Is Undervalued Despite Expected Tough Competition
02:43pm, Tuesday, 01'st Jun 2021
Mirum Is Undervalued Despite Expected Tough Competition
Albireo to Present at Upcoming Jefferies and William Blair Virtual Investor Conferences
08:30am, Wednesday, 26'th May 2021
BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief
Albireo's Bylvay Wins Positive Opinion from EMA For Rare Pediatric Liver Disease
12:48pm, Friday, 21'st May 2021
European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for
– Bylvay has the potential to become first approved drug to treat all forms of PFIC –
Albireo to Showcase New Data at 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition
08:30am, Wednesday, 19'th May 2021
- PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC -
